Overcoming Immunotherapy Resistance in Cancer: Current Approaches and Future Directions

Olugbenga Daramola

doi:10.35841/jmot-9.5.224

Opinion Article - Journal of Medical Oncology and Therapeutics (2024) Volume 9, Issue 5

Overcoming Immunotherapy Resistance in Cancer: Current Approaches and Future Directions

Olugbenga Daramola ^*

Department of Oncology, University of Lagos, Nigeria

*Corresponding Author:: Olugbenga Daramola
Department of Oncology, University of Lagos, Nigeria
E-mail: o.daramola@unilag.edu.ng

Received: 2-Sep-2024, Manuscript No. JMOT-24-146505; Editor assigned: 4-Sep-2024, PreQC No. JMOT-24-146505 (PQ) Reviewed:18-Sep-2024, QC No. JMOT-24-146505Revised:25-Sep-2024,Manuscript No. JMOT-24-146505; Published:30-Sep-2024,DOI: 10.35841/jmot- 9.5.224

Citation: Daramola O. Overcoming immunotherapy resistance in cancer: Current approaches and future directions. J Med Oncl Ther. 2024;9(5):224

Visit for more related articles at Journal of Medical Oncology and Therapeutics

Introduction

Immunotherapy has revolutionized cancer treatment, offering new hope for patients with previously untreatable or refractory cancers. By harnessing the body's immune system to target and destroy cancer cells, therapies like checkpoint inhibitors, CAR-T cells, and cancer vaccines have achieved remarkable success. However, despite these advances, a significant number of patients experience primary or acquired resistance to immunotherapy, leading to treatment failure and disease progression. Understanding and overcoming immunotherapy resistance is crucial for improving patient outcomes and extending the benefits of these innovative treatments [1].

Resistance to immunotherapy can arise through several mechanisms, which are broadly categorized into intrinsic and acquired resistance. Intrinsic resistance refers to a pre-existing condition where cancer cells are inherently unresponsive to immunotherapy from the outset. This can occur due to the absence of tumor antigens, defective antigen presentation machinery, or an immunosuppressive tumor microenvironment (TME). On the other hand, acquired resistance develops after an initial response to treatment, often due to adaptive changes in the tumor or the immune system. These changes include the upregulation of immune checkpoint molecules like PD-L1, loss of neoantigens, or the recruitment of regulatory T cells and myeloid-derived suppressor cells that inhibit immune activity [2].

The tumor microenvironment plays a critical role in mediating immunotherapy resistance. It is a complex ecosystem consisting of cancer cells, immune cells, stromal cells, and extracellular matrix components. Many tumors create an immunosuppressive microenvironment that prevents the immune system from effectively targeting cancer cells. Strategies to overcome this include the use of drugs that modulate the TME, such as inhibitors of vascular endothelial growth factor (VEGF), which can normalize blood vessels and improve immune cell infiltration. Additionally, therapies targeting the CXCL12/CXCR4 axis are being explored to disrupt the protective niche that some tumors create within the TME [3].

Effective immunotherapy relies on the immune system’s ability to recognize cancer-specific antigens. Some tumors evade immune detection by downregulating major histocompatibility complex (MHC) molecules or antigen-processing machinery, leading to poor antigen presentation. To counteract this, researchers are developing therapies that enhance antigen presentation, such as oncolytic viruses and cancer vaccines. These approaches aim to boost the visibility of cancer cells to the immune system, thereby improving the effectiveness of immunotherapy [4].

One promising approach to overcoming resistance is the use of combination therapies. Combining immunotherapy with other treatment modalities, such as chemotherapy, radiotherapy, or targeted therapies, can enhance the immune response and reduce resistance. For example, chemotherapy and radiotherapy can induce immunogenic cell death, releasing tumor antigens and promoting a more robust immune response. Additionally, combining checkpoint inhibitors with other immunotherapeutic agents, such as cytokines or co-stimulatory molecules, can synergistically enhance T-cell activation and persistence [5].

While PD-1/PD-L1 inhibitors have shown great promise, resistance to these agents is common. As a result, researchers are exploring other immune checkpoints as potential therapeutic targets. CTLA-4, LAG-3, TIM-3, and TIGIT are among the checkpoints being investigated in clinical trials. Targeting these molecules, either alone or in combination with PD-1/PD-L1 inhibitors, may help overcome resistance and extend the benefits of immunotherapy to a broader patient population [6].

Given the heterogeneity of tumors and the immune system, a one-size-fits-all approach to immunotherapy is unlikely to be effective for all patients. Personalized immunotherapy, which tailors treatment based on the genetic, molecular, and immunological characteristics of the patient’s tumor, is an emerging strategy to overcome resistance. Techniques such as next-generation sequencing and liquid biopsies allow for the identification of specific mutations, neoantigens, and immune profiles, enabling the design of customized treatment plans that are more likely to succeed [7].

Biomarkers are essential tools for predicting response to immunotherapy and identifying resistance mechanisms. PD-L1 expression, tumor mutational burden (TMB), and microsatellite instability (MSI) are currently used as biomarkers to guide immunotherapy decisions. However, these markers are not always reliable predictors of response. Ongoing research is focused on discovering new biomarkers, such as specific gene signatures or immune cell infiltration patterns, that can more accurately predict which patients will benefit from immunotherapy and when resistance is likely to occur [8].

Epigenetic changes, such as DNA methylation and histone modification, can influence gene expression and contribute to immunotherapy resistance. Epigenetic therapies, including DNA methyltransferase inhibitors and histone deacetylase inhibitors, are being investigated as a means to reverse resistance and enhance the effectiveness of immunotherapy. By modulating the expression of genes involved in immune evasion and antigen presentation, these therapies have the potential to restore sensitivity to immunotherapy [9].

The field of immunotherapy resistance research is rapidly evolving, with numerous clinical trials underway to test novel strategies for overcoming resistance. Advances in technologies such as single-cell sequencing, CRISPR-based gene editing, and high-dimensional immune profiling are providing deeper insights into the complex interactions between cancer cells and the immune system. These tools are helping to unravel the mechanisms of resistance and identify new therapeutic targets [10].

Conclusion

Overcoming immunotherapy resistance remains one of the biggest challenges in oncology, but the ongoing research and development of novel strategies offer hope for improving patient outcomes. By targeting the tumor microenvironment, enhancing antigen presentation, exploring combination therapies, and adopting personalized approaches, the medical community is making significant strides in addressing resistance. As our understanding of the mechanisms underlying resistance continues to grow, the future of immunotherapy in cancer treatment looks increasingly promising.